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Abstract 
Invasive  fungal  infections  (IFI)  are  an
important complication in pediatric haemato-
logical and oncological patients who undergo
intensive  chemotherapy  for  leukemia,  solid
tumour  at  advanced  stage  or  relapsed,  and
hematopoietic stem cell transplantation. The
incidence of IFI is lower than bacterial infec-
tion  but  mortality  rate  remains  high.  This
review is designed to help paediatric oncolo-
gists in choosing the appropriate anti-fungal
strategy and agents for prophylaxis, empirical,
pre-emptive and specific therapy on the basis
of published evidence.
Introduction
Despite the advent of advanced anti-fungal
agents, invasive fungal infections (IFI) remain
a major cause of morbidity and mortality in
neutropenic cancer patients. Risk classes are
well  stratified  for  adult  patients  but  not  for
children.1 In  a  recent  prospective  survey  of
Italian  Association  of  Pediatric  Hematology
Oncology (AIEOP) showed that IFI were more
frequent  in  pediatric  patients  with  acute
myeloid  leukaemia  (AML)  during  induction
therapy, acute lymphoblastic leukaemia (ALL),
relapsing non-Hodgkin Lymphoma (NHL) and
advanced stage or relapsing solid tumours.2
Prophylaxis, empirical and 
pre-emptive therapy
Few  data  are  available  in  paediatric
patients.  In  epidemiological  reports  on  chil-
dren the incidence of IFI ranged from 5-13%
with a peak of up to 24% in AML patients. Yeast
infections  have  represented  for  several
decades the prevalent etiology of proven IFI but
in recent years invasive aspergillosis (IA) is
continuously  increasing.2,3 Mortality  rates
remains high, with IA-related mortality rang-
ing from 33-55.6%.3,4 Given  this mortality rate,
behavioural measures strategies such as cook-
ing food, washing hands, wearing face masks
and using HEPA filters are needed to prevent
the risk of developing IFI. Recommendations
for adult patients have been recently issued by
leading  scientific  societies  without  covering
the pediatric aerea.5-7
In  adult  patients,  meta-analyses  indicated
that  anti-fungal  prophylaxis  significantly
reduced the incidence of IFI but not the overall
mortality.  A  randomised  controlled  study
reported  that  prophylaxis  with  posaconazole
significantly reduced the incidence of proven
and probable IFI in patients with AML.8
Regarding empirical therapy a recent meta-
analysis indicated that this strategy reduced
significantly the incidence of proven and prob-
able IFI in neutropenic patients but it was not
able to reduce overall mortality.9 The compari-
son of different anti-fungal agent used empiri-
cally,  particularly  azoles  vs liposomal
Amphotericin B, did not show any difference in
efficacy or mortality. 
To  minimise  prescription  of  unnecessary
anti-fungal  agents  every  diagnostic  efforts
should tried before. In the neutropenic adult
patients, Maertens et al.,10 observed that a pre-
emptive strategy, based on daily serum galac-
tomannan  antigenemia  testing,  computed
tomography  (CT)  scan,  and  bronchoalveolar
lavage reduced anti-fungal treatment by 78%
compared  with  empirical  therapy  without
affecting negatively survival. This approach is
feasible for IA but not studied adequately so far
for zygomycetes. 
Only one study11 compared pre-emptive and
empirical  strategies.  The  pre-emptive
approach was associated with a significantly
greater  incidence  of  IFI,  particularly  in
patients with acute leukemia in induction, but
it had no impact upon overall mortality.  The
study by Girmenia et al.,12 which was based on
an intensive diagnostic work-up that included
a daily galactomannan test for 3 consecutive
days and a chest CT scan, reported the pre-
emptive approach was associated with a 43%
reduction in anti-fungal agents compared with
the empirical. There was no undue delay in
starting therapy and a 63% survival rate was
achieved in patients with IFI.
In children the level of evidence for the use
of antifungal drugs is inferior than the adults
because  the  published  data  are  limited  and
based  mainly  on  retrospective  studies  or  on
studies  of  pharmacokinetic;  moreover,  the
antifungal  drugs  marketed  recently  have  no
paediatric indication (posaconazole, anidula-
fungin), or have an indication narrower than
the in vitro activity of the molecule (micafun-
gin). Consequently, differently from adults, no
specific guidelines are available for IFI in chil-
dren. We performed a literature search with
the aim assess the level of evidence for the use
of  antifungal  drugs  in  paediatric  patients
affected  by  IFI.  The  key  words  used  for  the
selection of the studies were antifungal pro-
phylaxis, antifungal empiric therapy, antifun-
gal  pre-emptive  therapy,  antifungal  therapy,
fungal  infections,  and  pediatric  malignancy.
The literature search was limited to English
language papers and the period analyzed was
from 1 January 1990 to 31 July 2010. Reference
list of papers selected by literature search was
also used as source, if necessary. The results of
the search were first discussed and scored by
the authors and then presented for the final
discussion and approval to an expert meeting
held in Florence on 12 and 13 October 2010
where the representatives of centers belong-
ing  to  Italian  Association  of  Paediatric
Hematology Oncology (AIEOP) attended. The
scoring  system  proposed  by  Infectious
Diseases Society of America was adopted to
define the quality of evidence and strength of
recommendations.
Table 1 summarizes the published studies
on antifungal prophylaxis. Most studies were
retrospective or phase II with a limited sample
size.  Moreover,  the  only  randomised  study13
with a large cohort of patients, dating back to
1994, did not satisfy current EORTC criteria for
fungi  classification.  Overall,  the  studies  on
prophylaxis were scored as C with an evidence
level of between II and III. The need of prophy-
laxis is still debated and depends on the type of
patients  managed  (high-risk  vs.  low-risk),
local incidence of IFI, type of fungi isolated,
attitude of the centre to intensive diagnostic
work-up in case of IFI is suspected, and finan-
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cial  resources.  We  concluded  that  no  strong
recommendation is possible for antifungal pro-
phylaxis  in  pediatric  patients.  However,  It
should be considered for all high risk patients
such  as  AML  during  induction,  acute
leukaemia and NHL in relapse, advanced stage
or relapsing solid tumours when local epidemi-
ology  data  show  an  incidence  of  IFI  higher
than usually reported in other centres or high-
er than in a recent past. The antifungal drugs
most  commonly  used  and  resulted  safe  and
active, in analyzed studies, were fluconazole
and  itraconazole,  liposomal  amphotericin-B,
and recently micafungin. The determination of
blood level is recommended when itraconazole
or other azoles are used.5
Differently  from  prophylaxis,  the  empiric
use of antifungal drugs has been investigated
in prospective controlled randomized studies.
In a multi-centre, randomised study recruiting
adults  and  children  Prentice14 reported  that
liposomal  amphotericin  B  was  more  effica-
cious  than  standard  amphotericin  B  in
patients with fever of unknown origin (FUO).
In a double-blind multi-center study Maertens
et al.15 showed that caspofungin was not infe-
rior to liposomal amphotericin B in children. A
recent  prospective,  randomised,  controlled
study  by  Italian  Association  of  Pediatric
Hematology Oncology (AIEOP) that evaluated
the empiric antifungal therapy in patients at
low and high-risk of IFI reported that no signif-
icant differences in the tolerability and effica-
cy of liposomal amphotericin B and caspofun-
gin  (Caselli  D.,  personal  communication).
Moreover,  in  the  low-risk  arm  the  patients
were randomised to three different treatment
i.e. caspofungin vs. liposomal amphotericin B
vs. no antifungal therapy. Success rate and 30-
day survival resulted similar in all three arms,
suggesting that the use of empiric antifungal
treatment is no more fundamental in this cat-
egory of patients. 
We concluded that empiric antifungal thera-
py has a level of evidence of BII in high-risk
patients. Liposomal amphotericin B and caspo-
fungin are the recommended drugs. In the low-
risk patients, this strategy is not of proven effi-
cacy and should be discouraged, while a care-
ful diagnostic work-up is recommended
Pre-emptive treatment is the new frontier of
early  antifungal  therapy  because  has  the
potential for reducing unnecessary antifungal
therapy given empirically on the basis of a per-
sisting neutropenic fever refractory to antibi-
otic treatment. The adoption of a pre-emptive
strategy needs a prompt diagnostic evaluation
with CT scan, galactomannan antigen, and 1-3
b-D-glucan antigen, as well as the performing
of brochoalveolar lavage (BAL). This diagnos-
tic panel may be difficult to perform in children
for several reasons. CT may need sedation in
younger children, may increase the  exposure
to radiation in case of repeated exams, or fre-
Article
Table 1. Summary of the main evidence-based indications for invasive fungal infections
therapy in immunocompromised patients.
Authors Patients  Antifungal  Results Grading
number prophylaxis
Cáp J, 1993  22 Fluconazole 1-4 mg/kg/die  IFI: 2 proven (9%)  C III
Ninane J,   502 Fluconazole 3 mg/kg vs  IFI: 2.1% in Fluconazole group; C II
1994 Nystatin 50.000 U/kg or oral 8.4% in Amphotericin B group
Amphotericin B 25 mg/kg/die
Uhlenbrock S,  29 Liposomal Amphotericin B  IFI:  C III
2001 1 mg/Kg 2 times/week vs early 5 probable; 
intervention 1 possible; 
no differences between 2 groups
Simon A, 2006  39 Itraconazole 6-8 mg/kg/die   IFI: 0 C III
Hovi L, 2007  98 Itraconazole 5mg/kg/die   117 febrile episodes; C II
or Fluconazole 5-8mg/kg/die  IFI: 2 proven;
if toxicity  27 possible
Kolve H, 2009  84 Liposomal Amphotericin B   Successfull:  C III
96.8% prophylaxis
87.9% empirical therapy
Kaya Z, 2009  154 Fluconazole 4-6 mg/kg/die    IFI:  C III
11 proven(7,2%);       
4 probable(2,6%);            
6 possible(3,8%)    
Kusuki S, 2009  40 Micafungin 3 mg/kg/die   IFI:   C III
1 proven; 
0 possible/probable; 
10 suspected 
Kobayashi R,  22 Itraconazole 5 mgl/kg/die    IFI:  C II
2010 1 possible; 
0 proven/probable  
Table 2. Summary of the main evidence-based indications for invasive fungal infections
therapy in immunocompromised patients.
Drug IA IA Candidiasis Rare mycosis
1st line therapy 2nd line therapy
Liposomal amphotericin B B II BII BII BII
Micafungin NE CII BI NE
Caspofungin CII BII BII NE
Voriconazole BII BII BII BII
Posaconazole NE CIII CIII CIII
Combination therapy CIII CII CIII CIII
IA, invasive aspergillosis; NE, no evidence.
Table 3. Dosage and label use of the common antifungal drugs.
Antifungal agent Authorized age group Recommended dose
L-AmB Licensed in children 1-5 mg/kg/d i.v.
No age range specified
Voriconazole > 2 years 2-12 yrs: 7 mg/kg every 12 h i.v.
Or 200 mg twice daily p.o.
12-18 yrs: 6 mg/kg every 12 h i.v.
Or 100-200 mg x 2 p.o.
Posaconazole >18 years 600-800 mg/day
No licence for children as yet
Caspofungin Licensed for use in children 2-18 yrs: 50 mg/mq daily i.v. loading 
dose 70 mg/mq
Micafungin Neonates to adults 2 mg/Kg/ d or 100 mg/day i.v. > 40 Kg
D-Amb: Amphotericin deossicolato; L-AMB: liposomal Amphotericin [Pediatric Reports 2011; 3:e6] [page 19]
quently may results in a specific sign. Burgos
et al.  reported that nodules and a specific infil-
trates were the most common findings in chil-
dren and, differently from adults, halo sign was
detected  in  only  6.5%  of  children  with  IA.4
Serum fungal antigen tests may be useful for
the  diagnosis  of  IA  in  pediatric  cancer
patients.  The  performance  of  serum  galac-
tomannan antigen has been show to be good in
children as in adults with regard to specificity
and NPV (negative predictive value). The less
sentivity of the test than adult patients could
be attributed to a high incidence of false posi-
tives due to the type of diet, the cross-reactivi-
ty with b-lactamic antibiotics commonly used
in children (penicillin, acid clavulanic/amoxi-
cillin), and cross-reactions with Bifidobacteria
lipoteic  acid  in  intestinal  micro-flora.16,17
Moreover, there is less experience of testing
galactomannan antigen in children who per-
formed a BAL. Scarce information is available
on the use of 1-3 b-D-glucan in children.
Altogether,  we  concluded  that  pre-emptive
therapy  strategy,  though  a  valid  option,  has
been not investigated adequately in the pedi-
atric patients so it is not possible to formulate
any recommendation on it. Therefore, prospec-
tive study are needed.  
Therapy for probable/proven
mycosis
Although prospective phase III studies are
almost lacking in children, several retrospec-
tive, case-control, or prospective phase II stud-
ies have been published on proven/probable IFI
in children. Table 2 and 3 summarize the level
of evidence for the single drugs in different
setting (first line IA, second line IA, candidia-
sis, non-Aspergillus mould infection) and the
recommended dosage. 
Polyenes
Liposomal amphotericin B has a broad-spec-
trum activity against the most common yeast
and mould species, while Aspergillus terreus,
Aspergillus  versicolor,  Aspergillus  flavus
(some), Scedosporium and Candida lusitaniae
are reported to be resistant. 
Liposomal amphotericin B was scored as BII
for the first and second line treatment of IA,  BI
for  invasive  candidiasis,  and  BIII  for  non-
aspergillus mould infections.18-21
Azoles
Triazoles are a class of drugs with a narrow-
er spectrum of action and less toxicity than
amphotericin B. Voriconazole is licensed for
children over 2 years old. It was scored BII both
for IA, candidiasis, and invasive infections by
Scedosporium and  Fusarium. The  use  of
voriconazole  as  targeted  therapy  in  children
was investigated by Walsh,22in 58 patients who
reported 42% complete and partial responses
and  7%  disease  stabilization.  Cesaro23 and
Yilmaz24 achieved similar results in a total of
34  patients  with  refractory  IA.  Recently,  the
therapeutic  drug  monitoring  has  been  sug-
gested to optimize the efficacy and prevent tox-
icity. In fact, voriconazole has many interac-
tions with other drugs that may influence its
escretion and require the modulation of the
daily dose. Posaconazole (PSZ), a second gen-
eration azole, has a spectrum of activity even
broader  than  voriconazole,  being  active  also
against zygomycetes, and a better safety pro-
file. The published data on pediatric use are
limited to 3 studies25-27 one assessed the phar-
macokinetic in a group of patients of 8-12 year-
old, one described the clinical response in 12
patients treated as salvage therapy and the last
one evaluated the clinical response on 15 pedi-
atric patients with proven/probable infections.
This last study reported an efficacy rate of 57%
against zygomycetes, 75% against moulds, 50%
against Aspergillus and 50% against candida
strains.26 Considering  that  posaconazole  is
currently not indicated for the pediatric age
and the limited data available, we scored it as
CIII, both for IA, candidiasis, and other mould
infections.  
Echinocandins
This new class of drugs inhibits membrane
beta 1,3 D-glucan and in fact blocks membrane
formation and stabilisation. Efficacy and toxic-
ity profiles are excellent although some strains
of candida (Candida guilliermondii and parap-
silosis)  and  rare  fungi  (Zygomycetes,
Cryptococcus,  Trichosporon,  Fusarium,
Scedosporium) intrinsincally less sensitive or
even resistant. Caspofungin, the first of this
new  class  of  drugs,  is  associated  with  rare
drug-drug interactions. One multi-centre study
reported an 81% success rate of caspofungin as
first-line therapy against documented candida
infections and a 50% success rate as rescue
therapy for IA.28 We scored caspofungin as BII
for the therapy of Candida and CII for the ther-
apy of IA Micafungin, which was approved as
first-line therapy against invasive and oropha-
ryngeal candidiasis in the newborn and older
children, was recently introduced into clinical
onco-haematology practice. Micafungin result-
ed non inferior to liposomal amphotericin B in
a recent prospective randomized study on inva-
sive  candidiasis.29 Moreover,  Denning  et  al.
found a response rate of 50% to micafungin
used alone or in combination with other anti-
fungal drugs for IA.30 We scored micafungin as
BII for invasive candidiasis and CII for IA.
Combination therapy 
Combination therapy (particularly polyenes
and azoles or polyenes plus echinocandins) is
used in several paediatric centres. Drug com-
binations are hypothesized to exert a synergic
action because different mechanisms of action
on the fungal cell are exploited, the spectrum
of action is widened and complementary phar-
macokinetic and dynamic properties come into
play. Most of reports on combination therapy
are  retrospective2-4,31,32 and  showed  that  this
strategy is safe and active both for IA, candidi-
asis, and other mould infection but evidence of
superior efficacy than monotherapy has been
found  so  far.  Considering  the  higher  costs,
combination therapy is optional and a matter
of further investigation, we scored its use as
CII as second line treatment for IA and CIII for
all other infections.  
In attempting to orientate paediatric oncolo-
gists  in  appropriate  choice  of  anti-fungal
agents for their patients, the evidence provid-
ed in this review leads to the conclusion that
the risks, benefits and costs of modern anti-
fungal therapy in children need to be carefully
weighed up, given the state of the art in adults
and the few reports in paediatric patients. 
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